- Home
- RELY vs DNLI Comparison
RELY vs DNLI Comparison
Compare RELY & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELY | DNLI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RELY | DNLI |
|---|---|---|
| Price | $13.77 | $17.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $26.00 | ★ $31.58 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,544,865,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.57 | $3,973.10 |
| P/E Ratio | $145.89 | ★ N/A |
| Revenue Growth | ★ 31.27 | N/A |
| 52 Week Low | $12.08 | $10.57 |
| 52 Week High | $27.32 | $24.35 |
Technical Indicators
Market Signals| Indicator | RELY | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 54.81 |
| Support Level | $13.06 | $17.88 |
| Resistance Level | $13.88 | $17.95 |
| Average True Range (ATR) | 0.41 | 0.85 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 55.07 | 68.85 |
Price Performance
Historical ComparisonAbout RELY Remitly Global Inc.
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.